Join Respira Therapeutics for a KOL webinar featuring Ioana R. Preston, MD (Tufts University School of Medicine) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss unmet needs among patients with pulmonary arterial hypertension (PAH).

The event will also highlight Respira’s lead product candidate, RT234 (vardenafil inhalation powder), which is being developed as a first-in-class pro re nata (“PRN” or “as-needed”) therapy to enable PAH patients to acutely increase exercise capacity and improve common exertional symptoms, such as breathlessness and fatigue.

RT234, an investigational product currently in Phase 2 development, has been demonstrated to improve hemodynamics, exercise capacity and exertional symptoms in PAH patients.

A live question and answer session will follow the moderated discussion.